improv drug distributor bad place
hangout upgrad buy
upgrad rate cardin under-perform buy
increas po slightli higher estim
ev/ebitda drug distributor whole one subgroup see best
posit manag outbreak need take
prescript chang realli move recent recess
meanwhil cah medic distribut busi benefit
high focu sell basic medic suppli given on-going shortag person
protect equip need hospit custom stock much inventori
possibl asid specif tie seen distinct turnaround
core busi benefit stabil custom base outsiz growth
largest custom stabil medic busi move
challeng associ cordi medtron patient safeti
acquisit all-in stabl busi serv necessari function
outbreak steadi cash flow dividend yield hope end sight
opioid litig undemand valuat rel peer group
market see appeal risk/reward thu move buy rate
estim adjust higher medical/st pharma
given outbreak cah role suppli channel increas
estim account increas demand medic well like cushion
pharma stabl gener price increas medic organ growth
estim remaind addit
also increas pharma organ growth estim
account increas ep
ep would note alreadi consensu
year prior adjust
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
rx suppli chain script growth
rough ballpark w/last month
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
one largest drug medic product
two-third profit pharmaceut
busi nearli one-third medic
support retail/mail/hospital/physician client
well drug manufactur medic busi
manufactur portfolio medic
product distribut brand-nam product
hospit physician compani base
buy rate driven increas
stabil across segment potenti
upsid due on-going increas healthcar
demand steadi rx growth improv
gener deflat trend drive stabl
pharma growth annual oper
headwind plu increas demand
key driver medic perform
strong health dividend yield see
thesi pictur
exhibit gener deflat stabil long-term basi brand inflat remain steadi
exhibit calendar-adjust script trend tick across market
exhibit choppi period medic oper perform recent stabil easi comp help improv profit growth
compani file bofa global research estim
exhibit long-term basi under-perform respect
price object ep multipl five-year
averag discount incorpor margin price pressur
pharmaceut segment slow brand inflat increas competit
downstream independ buy group discount medic segment
incorpor grow risk non-tradit distributor
upsid risk po potenti volum pickup increas buyside/sellsid
spread faster-than-expect contribut recent acquir medic
busi capit deploy downsid risk po increment wors
drug price pressur increas competit creat gross profit headwind risk
amazon anoth disrupt forc enter suppli chain market on-going
uncertainti headlin relat opioid litig process medic
revenue/profit shortfal relat surgic gown kit recal potenti
michael cherni herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
